{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.8"},{"groupId":"OG001","value":"88.6"},{"groupId":"OG002","value":"85.0"}]}],"title":"Q3. Answer: FDC SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"6.3"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q3. Answer: P+H IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"5.0"}]}],"title":"Q3. Answer: No Difference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"7.5"}]}],"title":"Q3. Answer: Unsure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q3. Answer: Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.2"},{"groupId":"OG001","value":"79.7"},{"groupId":"OG002","value":"78.8"}]}],"title":"Q4. Answer: FDC SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"3.8"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q4. Answer: P+H IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6"},{"groupId":"OG001","value":"12.7"},{"groupId":"OG002","value":"12.5"}]}],"title":"Q4. Answer: No Difference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8"},{"groupId":"OG001","value":"1.3"},{"groupId":"OG002","value":"6.3"}]}],"title":"Q4. Answer: Unsure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q4. Answer: Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6"},{"groupId":"OG001","value":"94.9"},{"groupId":"OG002","value":"96.3"}]}],"title":"Q5. Answer: FDC SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Q5. Answer: P+H IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"2.5"}]}],"title":"Q5. Answer: No Difference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Q5. Answer: Unsure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q5. Answer: Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2"},{"groupId":"OG001","value":"83.5"},{"groupId":"OG002","value":"88.8"}]}],"title":"Q6. Answer: FDC SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q6. Answer: P+H IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3"},{"groupId":"OG001","value":"13.9"},{"groupId":"OG002","value":"8.8"}]}],"title":"Q6. Answer: No Difference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"}]}],"title":"Q6. Answer: Unsure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q6. Answer: Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.4"},{"groupId":"OG001","value":"77.2"},{"groupId":"OG002","value":"77.5"}]}],"title":"Q7. Answer: FDC SC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3"},{"groupId":"OG001","value":"7.6"},{"groupId":"OG002","value":"5.0"}]}],"title":"Q7. Answer: P+H IV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"2.5"}]}],"title":"Q7. Answer: No Difference"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9"},{"groupId":"OG001","value":"10.1"},{"groupId":"OG002","value":"13.8"}]}],"title":"Q7. Answer: Unsure"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9"},{"groupId":"OG001","value":"2.5"},{"groupId":"OG002","value":"1.3"}]}],"title":"Q7. Answer: Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"159"},{"groupId":"OG001","value":"79"},{"groupId":"OG002","value":"80"}],"units":"Participants"}],"description":"Healthcare professionals (HCPs) who administered study treatment responded at Cycle 6 of the Treatment Cross-Over Period to the following HCPQ-Treatment Room Questions 3 to 7: \"Looking back over the Perjeta-Herceptin treatment sessions, please indicate based on your opinion which administration method: Q3. Which Method Was Most Convenient for the Patient? Q4. Which Method Was Best for Optimizing Patient Care in Your Centre? Q5. Which Method Took the Least Time from Start to Finish of Administration? Q6. Which Method Required the Least Resource Use for Administration? Q7. Which Method Was Preferred by Patients?\" The four available response options were: P+H IV, FDC SC, No Difference, and Unsure.","groups":[{"description":"This analysis set includes all healthcare professionals who treated participants from Arms A and B and completed the HCPQ questionnaire, which was administered at the last treatment cycle in the Treatment Cross-Over Period of the study. During the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Healthcare Professionals"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"A: P+H IV Followed by PH FDC SC"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG002","title":"B: PH FDC SC Followed by P+H IV"}],"paramType":"NUMBER","populationDescription":"The number analyzed includes HCPs who completed any part of the survey at treatment Cycle 6.","reportingStatus":"POSTED","timeFrame":"Day 1 of Cycle 6 (each cycle is 21 days)","title":"Percentage of Healthcare Professionals (HCPs) by Their Responses on Perception of Time/Resource Use and Convenience of Each Study Regimen, Questions 3 to 7 of the HCPQ - Treatment Room","type":"SECONDARY","unitOfMeasure":"Percentage of HCPs"}